The specific cellular influx and efflux of inflammatory cells into specific components of the mammalian lung is a major characteristic of several pulmonary toxic syndromes. This is also true, of course, for most pulmonary clinical syndromes (e.g., bronchitis, emphysema, cigarette smoke poisoning, acute respiratory distress syndromes) or the many granulomatous syndromes (eosinophilic granuloma, Wegner's granuloma, Boeck's sarcoid) observed in man. Each of these syndromes is characterized by influx and accumulation of specific inflammatory cells into specific pulmonary compartments.
There is now considerable information concerning the nonspecific influx of inflammatory cells into damaged tissues. However, little understanding concerning specific cellular influxes is available, and essentially no data are available concerning cellular efflux from healing tissues. An understanding of the clinical syndromes listed above in which the residence time of specific inflammatory cells in lung can be very long-of the order of years-is crucial to establish therapeutic or etiologic approaches to these diseases.
Multiple substances, whether inhaled or injected intratracheally or intravenously, will cause the accumulation of various inflammatory cells in various areas of the mammalian lung. For example, intratracheal injec- (4) .
In other species, however, e.g., fowl or amphibia, inflammatory cells do not invade the lung with exposure to intratracheal silica, intravenous Freund's adjuvant or hyperbaric oxygen (5, 6) . In fact, fowl lungs suffer no observable acute or chronic damage from hyperbaric oxygen or from intratracheal injection of silica or Freund's adjuvant (6) . Thus, it is clear that different mechanisms exist, in various species, for controlling the efflux and accumulation of specific inflammatory cells in localized areas of the lung.
Since in these species those lungs are not damaged by known lung toxins, there is also no inflammatory cell influx, it is possible that much of the lung cell damage seen in mammalian lung diseases is the result of the cytotoxic capabilities of the inflammatory system itself.
The above observations, suggesting that the chronic lung damage seen clinically and after toxic exposures of mammals-but not nonmammalian species-may be the result of the destructive capabilities of the invading inflammatory cells themselves have raised three therapeutically important questions (7) Peptides. The peptides include synthetic peptides as well as many naturally occurring ones, e.g., various formylated peptides (9), specific fragments from complement (C5a) (11) , and helper peptides (12), a-globulins, collagen (13) , elastin (14) and fibronectin (15) . These peptides are also known to bind to different cell surface receptors present in varying amounts on granulocytes but not on lymphocytes (16, 17) . Binding of these receptors to their respective ligands is stoichiometrically related to degree of motility. Although optimal motility is observed when these peptides are presented to the cell in a concentration gradient (chemotaxis), these peptides also activate motility in the absence of a concentration gradient (chemokinesis). The magnitude of the nondirected migratory response in vitro depends on the concentration of cells, i.e., the freedom of the cells to move laterally, rather than vertically, through filters (18) .
Chemical alteration of the peptide bond by N-alkylation of the synthetic chemotaxin, formyl-met-phe, causes a complete loss of binding to the formyl peptide receptor. However, some of the biologic activities, e.g., chemokinesis, inhibition of O2-production, of these peptide analogs remain (19) . This indicates that the peptide bond itself is not necessary for all cell biologic functions of chemotactic peptides. Likewise, the clinical specificity of the receptor for the synthetic formyl peptides has been shown to be nonspecific. Pyrazolon anti-inflammagens, e.g., phenyl butazone, specifically inhibit binding of F-met-leu-phe to its receptor on human neutrophils (20) .
Many uncharacterized biologic peptides with chemoattractant activities are also produced by various cells, e.g., lymphocytes, macrophages, mast cells and tumor cells in culture (21) (22) (23) (24) . It is not known if all these various cytotaxins have specific receptors, but it is clear that these agents possess marginal specificity for different cell types. Both polymorphonuclear leukocytes (PMNL), monocytes and alveolar or peritoneal macrophages are all stimulated by these peptides. However, it was recently shown that peptides containing desmosine (14) , as well as desmosine itself are much more chemotactic for blood monocytes than for blood PMNL or alveolar macrophages. Fragments of fibronectin also appear to be somewhat specific cytotaxins for fibroblasts (15) . An uncharacterized neutral substance of low molecular weight produced by human alveolar macrophages upon stimulation exhibit some specificity for neutrophils (25) . The biologically derived acidic tetrapeptide has also been shown to be somewhat specific for motility of mammalian eosinophils (21), but it is not clear if this tetrapeptide is a major cytotaxin in vivo, since eosinophils also respond to many of the above peptides as well.
Fatty Acids. Two biologic unsaturated fatty acids, arachidonic and linoleic and their products, appear to be the major fatty acids involved in in vivo cytotaxis (10, 26, 27) . Many of the oxidation products of arachidonic acid, e.g., prostaglandin E1, the various monohydroperoxy and monohydroxy, i.e., 5-, 12-and 15-, eicosatetraenoic acids, and 5,12-dihydroxyeicosatetraenoic acid (8, 28) as well as many uncharacterized photonactivated oxidation products of arachidonic acid (10) all exhibit chemoattractant properties in vitro. Arachidonic acid itself is also a powerful nonspecific attractant, even under conditions in which many of its metabolic pathways are inhibited. However, since arachidonic acid is so metabolically active, this acid does not usually accumulate in amounts sufficient to be physiologically active (29) . Linoleic acid, however, does accumulate in considerable amounts, following injury, in body cavities, e.g., airways, pleura, and peritoneum (27) . Various oxidation products of arachidonic acid, especially the hydroxy acids (30) , also accumulate. In contrast to the peptides, however, these fatty acids are not bound by specific cell surface receptors on human PMNL (26) . The mechanism by which these fatty acids activate motility is chemokinetic in type (18) . Thus, chemotaxis which is the result of specific ligand-receptor interactions is usually not observed with the fatty acids.
The fatty acids, like the peptides, also possess cellular specificity. In fact, the only agent, thus far described that specifically attracts alveolar macrophages but not blood granulocytes is linoleic acid (18) . This mechanism for linoleic acid attraction of macrophages is chemokinetic. Since the time course for influx and efflux of linoleic acid following injury in both airways of rabbits and in pleura of rats (26) closely parallels the influx and efflux of macrophages, it is likely that this chemokinetic mechanism which is stimulated by linoleic acid is operative in macrophage motility in vivo.
The source of this extravascular linoleic acid is probably the resident macrophages themselves. Stimulation of the isolated resident alveolar or pleural macrophages in vitro by agents such as zymosan or silica particles, phorbol esters, or calcium ionophores, causes a massive efflux of linoleic and other fatty acids from these cells. These fatty acids are derived almost exclusively from the phosphatidylcholines within these cells (26) . Since essentially no arachidonic acid is liberated from these cells and since much of the secreted chemoattractant activities in these extracellular lavages can be accounted for as linoleic acid, it is likely that resident extravascular macrophages account, at least in part, for the accumulation of the cell-specific cytotaxin, linoleic acid, in injured extravascular spaces in mammals.
The above concept of the role of the secretions of resident inflammatory cells in extravascular spaces of mammals is supported by recent observations on other species. Essentially, no macrophages can be removed by lung lavage from fowl (6) (chickens) or amphibia (bull frogs) (5) . These species also do not accumulate pulmonary inflammatory cells when exposed to hyperbaric oxygen or intratracheal respirable silica particles; nor does linoleic acid accumulate after exposure in airways of these two species; nor do these species suffer the hemorrhagic edematous lung damage seen in mammals exposed to hyperbaric oxygen (5 
Inflammatory Cell Cytotoxicity
The above considerations implicating the inflammatory system as etiologic in many environmental toxic syndromes make it imperative that we understand how the cytotoxic potential of the inflammatory system is controlled. Three major cytotoxic systems are known, i.e., neutral proteases (31), neutral phospholipases and their inhibitors (26, 32) and the oxidant-radical-producing system (33) . The latter system is localized primarily in blood granulocytes, whereas the two hydrolase systems are localized primarily in macrophages.
The immune system, of course, with its vast array of monoclonal specificity is primarily concerned with focusing the above cytotoxic systems. With its capacity to recognize specific cells, either foreign or domestic, it directs the cytotoxic cells to their assigned target. This immunologic recognition and direction is beyond the scope of this review and is not further discussed. It is clear, however, that the cytotoxic system can work equally well either on its own direction or as directed by the immune system. This discussion is concerned only with the self-directed cytotoxic mechanisms of granulocyte and macrophages.
Oxidant Radical Production
Oxygen-derived radicals produce hydroxylated purines or pyrimidines, lipid hydroperoxides, auto-oxidized products of thiols or amines, as well as depolymerized polysaccharides (33) . Under ambient conditions, the major cellular source of extracellular oxidants (O2-, H202, OH) is PMNL. Macrophages and fibroblast secrete considerably lesser amounts (34) . Under hyperoxic conditions, however, it is likely that oxidant radical production (by cytoplasmic oxidases, mitochondrial oxidases and microsomal oxidases) by most cells can increase to a degree that the intracellular scavengers (superoxide dismutase, glutathione reductase, catalase, prostaglandin and thromboxane synthetase and lipoxygenase) as well as the extracellular scavenger, superoxide dismutase (35) , fail to control intracellular concentrations. This leads to the various types of cell damage as indicated above, with the result that all cells can be potentially destroyed by internal oxidants.
At ambient conditions, cytotoxic destruction by extracellular oxidants is most likely the work of PMNL. The control of oxidant secretion in PMNL remains poorly understood. Almost any surface-active molecule, e.g., hydrophobic peptides, unsaturated fatty acids, digitonin, phorbol esters, calcium ionophores, cytochalasins, etc., will all activate this process (36, 37) . 02 appears to be the major excretory product (38) , but the toxic species is the hydroxyl radical (39) . The only known way to inhibit this process is to remove a bound protease from these cells, either by extensive washing, or by displacement of the protease by small amounts of formylated peptides or cytotactic fatty acids or by inhibition of the protease by addition of protease inhibitors (40) . However, once the secretion of radicals is fully activated, e.g., by ionophores, digitonin or phorbol esters, the protease inhibitors are ineffective. Also, there are no other known inhibitors. Secretion of destructive oxidant radicals by leukocytes, therefore, is a process which is readily triggered by very low concentrations of innumerable small molecules, but in contrast to the other inflammatory systems, there is no known mechanism to inhibit this oxidant radical system, once it is fully activated.
Phospholipases
There is no evidence that inflammatory cells secrete phospholipases for cytotoxic purposes. However, as indicated above, macrophages, when stimulated, activate a phospholipase A2 which liberates biologically active fatty acids, e.g., linoleic acid. Similarly, activation of a phospholipase in neutrophils results in the liberation of hydroxy fatty acids, e.g., 5-hydroxyeicosatetraenoic and 5,12-dihydroxyeicosatetraenoic. Thus, the function of these activatable phospholipases is to produce products which attract specific inflammatory cells.
Neutral Proteases
Neutral proteases, secreted both by activated macrophages and by PMNL may be directly involved in tissue destruction.
The elastase of PMNL and macrophages (41) destroy extracellular structures (elastin) (42) whereas the neutral proteases of macrophages are directly cytotoxic (31) . The involvement of inflammatory proteases, e.g., neutrophil elastase in clinical lung destruction (emphysema) is now generally accepted (43) . Toxic oxidants such as cigarette smoke, or oxidant radicals, produced by activated neutrophils, directly inactivate the protease inhibitor, a1-trypsin inhibitor (5) . This destruction of the natural inhibitor of the elastase results in the excessive destruction of elastin by neutrophil elastase with the development of pulmonary emphysema. It is not clear if hydrolytic enzymes of macrophages are also involved in pulmonary destruction. These macrophage cytotoxic proteases may be involved in tumor surveillance (31) or in autoimmune mechanisms which result in destruction of normal cells (44) . It is possible that pulmonary tissue-specific antigen is involved in some of the many granulomatous pulmonary syndromes seen in man in which macrophages are the effector cells present. Example of such syndromes involving tissue specific antigens in other organs include multiple sclerosis (45) , thyroiditis (46) and chronic bowel disease (29) . In these various syndromes, it is unclear whether killer T-lymphocytes or macrophages are the cytotoxic effector cells and also if neutral hydrolases or oxidant radicals are the cytotoxic molecules.
